- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
USV Expands Diabetes Portfolio with Cost-Effective Liralin-EP in India - Video
Overview
USV Pvt. Ltd., launches the Liralin EP a combination of Linagliptin & Empagliflozin at just Rs 12.90 per tablet for strengthening it's affordable diabetes care range. Liralin EP contains the world's 1st approved DPP4i + SGLT2i combination for the management.
It is available in two strengths to cater to varied patient needs- Liralin-EP 10 contains Empagliflozin 10 mg and Linagliptin 5 mg, while Liralin-EP 25 contains Empagliflozin 25 mg and Linagliptin 5 mg.
Given the loss of patency of Empagliflozin in India, USV has priced the drug at very affordable levels for the convenience of patients. Liralin-EP 10 at ₹12.90 per tablet and Liralin-EP 25 at ₹13.90 per tablet, making quality diabetes management accessible to a wider patient population across India.
Liralin-EP combines Linagliptin, a DPP-4 inhibitor, with Empagliflozin, an SGLT2 inhibitor, offering complementary mechanisms to effectively lower blood glucose levels while providing added cardiovascular and renal benefits.
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)